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Abstract
Atrial fibrillation (AF) and coronary artery disease requiring percu-
taneous coronary intervention (PCI) and stenting often coexist in older
patients. This poses the difficult problem of concurrent anticoagulant
and double antiplatelet therapy (triple therapy). Current treatment
guidelines do recommend triple therapy, especially in the course of
acute coronary syndrome (ACS), with limitations due to an excessive
risk of bleeding associated with this therapeutic regimen. This review
summarizes randomized clinical trials and observational studies that
compared triple therapy with a variety of different therapeutic options.
Although the available evidence is not completely satisfactory and other
studies are urgently needed, alternative regimens to triple therapy in
AF patients undergoing PCI and stenting are promising, at least in
terms of safety.
Introduction
Atrial fibrillation (AF) is the most common tachyarrhythmia of late
life, affecting approximately 5% of older persons. Prevalence increases
from 4.3% in subjects aged 66-69 years to 5.4% above the age of 90; sim-
ilar age-related trends have been reported for incidence [1]. Episodes
of clinically unrecognized atrial fibrillation are frequent in individuals
with no documented history of the arrhythmia and may be responsible
for thromboembolism of unknown origin, which is mostly represented
by stroke. Following current guidelines, an oral anticoagulant (OAC) is
recommended for patients with AF and a CHA2DS2-VASc score ≥1 in
men and 2 in women to prevent thromboembolism [2-4].
Coronary artery disease coexists in as many as 30 to 60% of AF pa-
tients and it is estimated that about 5–15% of AF patients will undergo
percutaneous coronary intervention (PCI) and stenting at some point
in their lives [2]. As a consequence, the need for triple therapy, i.e. co-
existent prescription of OAC, traditionally vitamin K antagonists
(VKA), and dual antiplatelet therapy (DAPT) with aspirin and the P2Y12
antagonist clopidogrel, often emerges. Although effective in reducing
thromboembolic risk, the combination of DAPT with OAC bears a sub-
stantial risk of bleeding, which can be suggested by a HAS-BLED score
of ≥3 [4]. The balance between stroke and bleeding risks is particularly
delicate in older patients, making the issue of triple therapy highly con-
troversial. Moreover, newer therapeutic agents, such as P2Y12 antago-
nists more potent than clopidogrel, and non-VKA, direct oral anticoag-
ulants (DOAC) are nowadays available for the prevention of stent
thrombosis and AF-related stroke, respectively. Thus, several possible
therapeutic scenarios should be considered.
Clinical practice guidelines
Compared to other current practice guidelines on AF, those issued in
2016 by the European Society of Cardiology (ESC) [2] discuss the topic
of triple therapy more extensively. In patients with AF, conventional
triple therapy (aspirin 75-100 mg/day, clopidogrel 75 mg/day, and VKA)
is recommended for 1 month after elective PCI and for 1 (in case of
bleeding high risk) to 6 months (when the risk of bleeding is low) after
primary PCI in the setting of ACS, followed by dual therapy (OAC and
only one antiplatelet agent) for the time being through 1 year, then by
OAC monotherapy. Treatment with any OAC plus clopidogrel 75 mg/day
is deemed as an alternative to initial therapy in selected patients. Yet,
these guidelines were issued without an undisputable evidence sup-
port: randomized clinical trials (RCT) are scarce and, if ever, cast
doubts on triple therapy as the most appropriate treatment in AF pa-
tients receiving PCI after ACS.
Evidence from randomized clinical trials
Only three RCT have been conducted, two before and one after the
publication of the ESC guidelines. The WOEST study enrolled 573 pa-
tients on warfarin and PCI to warfarin plus DAPT versus a double
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Other evidence
Observational studies, in general deriving from clinical registries,
are frequently considered to complement, from the “real-world”, evi-
dence provided by RCT. In a registry study of 12165 patients with AF, un-
dergoing primary PCI of ACS, Lamberts et al. reported that triple
therapy was associated with a non-significant increase in both risk of
bleeding (HR 1.28, 95% CI 0.89-1.82) and of myocardial infarction or
coronary death (HR 1.45, 95% CI 1.00-2.08) in 1 year [8]. The risk of
bleeding, but not that of thromboembolism, was significantly greater
with triple therapy in a registry study of approximately 5000 patients
[9] and in a meta-analysis of more than 7100 patients [10], in which
this treatment was compared with clopidogrel-based dual therapy.
Data on newer P2Y12 antagonists are usually more limited in terms
of sample size, follow-up duration, and design [11, 12]: however, in
none of the available investigations, including a large (n=11756) ob-
servational study comparing prasugrel plus OAC vs. clopidogrel plus
OAC in a 6-month follow-up [12], triple therapy was more effective or
safer than the comparator.
Two other meta-analyses addressing this theme have been con-
ducted. In the first one, 14 observational studies (including conference
proceedings) and 2 RCT were pooled, comparing triple therapy with dif-
ferent regimens of OAC (given with a variety of indications besides AF)
associated with one single antiplatelet agent [13]. Mortality and other
efficacy endpoints were less frequent in subjects receiving triple
therapy, although with a substantial degree of heterogeneity that makes
the result of the study uncertain; bleeding was significantly more
common in subjects receiving triple therapy. Safety of this regimen was
inferior, with neutral findings on the efficacy endpoints, in another
meta-analysis that included 9 observational studies and 2 RCT [14].
Conclusions
Evidence does not unequivocally support the use of the guideline-rec-
ommended triple therapy in patients with AF and recent PCI for ACS.
From the 3 RCT available, alternative regimens based on clopidogrel plus
VKA, or a DOAC plus different antiplatelet agents, are at least as effective
and definitively safer in patients with diverse indications to PCI and
stenting. If this evidence can be strictly applied in the setting of ACS, al-
though reasonable, remains so far unproven. Observational studies seem
to confirm, in a real-world setting, that alternatives to triple therapy are
safer and possibly non-inferior. Meta-analyses had poor methodological
quality and reported conflicting results on efficacy, whereas they con-
firmed that safety of triple therapy was lower than that of the compara-
tors. The available evidence, although not adequate to indicate a defini-
tively preferable alternative, appear sufficient to question the totem of
triple therapy in AF patients undergoing PCI and stenting, at least for
safety reasons. For the practicing physician, it is also important to rec-
ognize that avoiding triple therapy may help reduce the complexity of a
therapeutic regimen, thus contributing to limit problems such poor drug
adherence and drug overload (polypharmacy), typical of older patients.
As summarized by Chang et al. [15], at least 6 RCT are currently on-
going, comparing a variety of therapeutic options (mostly based upon
DAOC) to triple therapy. Of them, the APPROACH study will specifically
focus on patients with ACS, who are randomized to apixaban plus clopi-
dogrel versus triple therapy. While the results of this and other studies
are urgently needed, it should be pointed out that none of the available
investigations and, as far as it can be argued from the design studies,
also of those under way, considered outcomes other than death, car-
diovascular events, and clinically significant bleedings. Even “minor”
therapy regimen of warfarin plus clopidogrel. After a 1-year follow-up,
the primary endpoint of any bleeding episode was reached in 44.4% of
participants in the triple therapy group, compared to only 19.4% in the
double therapy group, with an HR (95% CI) of 0.36 (0.26-0.50).
Somehow unexpectedly, also the secondary endpoints of all-cause
death (triple: 6.3%, double: 2.5%) and a composite endpoint of death,
myocardial infarction, stroke, target-vessel revascularization, and
stent thrombosis (triple: 17.6%, double: 11.1%) were significantly pre-
vented by the double therapy, with HR of 0.39 (0.16-0.93) and 0.60
(0.38-0.94) [5]. Thus, the combination of warfarin and clopidogrel ap-
peared more effective and safer than triple therapy. Nevertheless, ap-
plicability of these findings to AF patients treated with PCI for ACS
should be cautious, because only 70% of participants in the WOEST
trial were on warfarin for AF and a minority (30%) had received PCI in
the course of ACS.
The PIONEER RCT opened a new scenario, by introducing a DAOC
as a comparator to VKA in a combined anticoagulant-antiplatelet
therapeutic schedule. A total of 2024 patients, all with AF, were ran-
domized to three therapeutic regimens, i.e. rivaroxaban 15 mg/day
plus a P2Y12 antagonist (group 1), rivaroxaban at the unusually low
dose of 5 mg/day plus DAPT (group 2), and VKA plus DAPT (group 3).
Clopidogrel was the P2Y12 antagonist used in approximately 95% of
cases. After 1-year follow-up, bleeding episodes were significantly
less frequent in groups 1 and 2 than in group 3, with HR of 0.59
(0.47-0.76) and 0.63 (0.50-0.80), respectively, and incidence of
bleeding of 17.4% in the two groups receiving rivaroxaban combined,
versus 26.7% in group 3. Incidence of major cardiovascular events
was comparable across the groups. Groups 1 and 2 had similar inci-
dence of both safety and efficacy endpoints. These findings indicate
that rivaroxaban, associated with a P2Y12 antagonist or with DAPT, is
better than warfarin in terms of bleeding risk and not inferior for ef-
ficacy [6]. Strength of the study was enrolment of AF patients only,
whereas a limitation was that the standard dose of rivaroxaban used
for AF is 20 and not 15 mg/day, which was selected in order to reduce
risk of bleeding.
In the more recent RE-DUAL PCI trial, Cannon et al. [7] evaluated
a different DAOC, dabigatran, randomly assigning 2725 patients with
AF and PCI to three possible therapeutic alternatives: dual therapy
with dabigatran (110 mg twice daily) plus either clopidogrel (75 mg
daily) or ticagrelor (90 mg/day), dual therapy with dabigatran (150
mg twice daily) plus either clopidogrel or ticagrelor, or triple therapy
with warfarin plus aspirin (≤100 mg daily) and either clopidogrel or
ticagrelor. In the triple therapy group, aspirin was discontinued after
1 or 3 months, depending on whether a bare-metal or a drug-eluting
stent had been implanted. Primary endpoint was bleeding, whereas a
main secondary efficacy endpoint combined thromboembolic events
(myocardial infarction, stroke, or systemic embolism), death, or un-
planned revascularization (either interventional or surgical). Com-
pared to triple therapy, incidence of the primary safety endpoint was
lower in both dual therapy arms, with HR of 0.52 (0.42–0.63) and 0.72
(0.58–0.88), respectively; combined, the two dabigatran-based dual
therapy regimens conferred the same protection as triple therapy to-
wards the secondary efficacy endpoint, with HR of 1.04 (0.84–1.29)
[7]. However, it should be taken into account that in the RE-DUAL
PCI study indication to PCI was ACS in approximately 50% of cases
only.
Taken together, the results of these three randomized trials suggest
that newer, diverse therapeutic approaches, which reject the paradigm
of aspirin and VKA as the cornerstones to prevent thromboembolism in
PCI with stenting and AF, respectively, are at least as effective and de-
finitively safer than the time-honored triple therapy in patients with AF
undergoing PCI, although not always in the context of ACS.
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bleedings, as well as subclinical cerebrovascular events, may induce a
substantial decline in functional and cognitive status of older persons,
who are frequent candidates to triple therapy. Moreover, age-related
frailty [16] may disproportionately amplify the negative effects of
thromboembolism and bleeding. Thus, evidence so far provided on the
issue of efficacy and safety of triple therapy and alternatives to it is
largely unsatisfactory in terms of specific geriatric outcomes.
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